Home / Business and Economy / Strides Pharma Sells Stake for ₹230 Cr

Strides Pharma Sells Stake for ₹230 Cr

27 Jun

Summary

Strides Pharma to gain ₹100 crore from Pivot Path stake sale.
Ascent Capital leads investment valuing Pivot Path at ₹230 crore.
Pivot Path receives ₹50 crore capital for growth initiatives.

Strides Pharma Science Limited is monetizing its stake in its wholly owned subsidiary, Pivot Path Private Limited. The transaction, spearheaded by Ascent Capital Advisors India Pvt Ltd and co-investor Vintage Classic, values Pivot Path at approximately ₹230 crore post-money. This move will see Strides Pharma realize about ₹100 crore in proceeds while maintaining a 20% stake in the subsidiary.

Pivot Path will also receive a primary capital infusion of ₹50 crore, intended to support its expansion and technological advancements. Following this deal, Pivot Path will be reclassified as an associate company of Strides Pharma Science. The carved-out business reported FY26 revenue of ₹1,447 million and EBITDA of ₹169 million.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.